TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Research reports from D. Lechner and co-authors provide new insights into tuberculosis
August 26th, 2008
According to recent research from Graz, Austria, "One-third of the world's population is infected with the dormant tuberculosis bacillus, and there have been no new antimycobacterial compounds with new modes of action for over 30 years. Extensively drug-resistant tuberculosis is resistant to first- and second-line drugs, which can have severe side effects, and requires the breakthrough of new antituberculotics and resistance-modifying agents." "Efflux pumps can cause multidrug resistance and have recently evoked much interest as promising new targets in antimicrobial therapy. The study was performed to set up an ethidium bromide (EtBr) efflux assay in Mycobacterium...
Source: TB & Outbreaks Week (2008-08-26)
|
